FDA seeks public input on early-phase ibogaine trial design
FDA Seeks Public Input to Support Ibogaine Research
The US Food and Drug Administration has issued a request for information on approaches it is considering for the design of early-phase clinical trials of ibogaine drug products, and is seeking public comment.
The request sets out the protocol questions the agency wants answered, including a starting dose cap, so researchers and sponsors can see what evidence the FDA expects before early-phase ibogaine trials proceed.
Key facts
- Kind of item
- Guidance and consultations
- Compound
- Ibogaine
- Regulator
- FDA (United States)
- Jurisdiction
- United States
- Source
- FDA: press announcements (US) (fda.gov)
- Published
- Original
- Read it at fda.gov
How this summary was made
The summary and the “Why it matters” note were written by an AI model from the linked source, and a model scored the item against this site's editorial criteria. The facts above come from the item's topics and from identifiers written out in the stored text. Anything not found there is left out, so a missing row means not stated, not no. Read the original before relying on any detail. Editorial method
Source: FDA: press announcements (US) · fda.gov
Connected to
- Kind of item
- Guidance and consultations
- Compound
- Ibogaine
- Regulator
- FDA (United States)
- Jurisdiction
- United States